Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The aim of this study is to evaluate modulation of anti-tumor T cell responses in cancer patients treated by concomitant radiochemotherapy (i-RTCT)
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Biological samples | Experimental | Blood samples will be collected at baseline, at J15/J20 after RTCT initiation, and then 1 month, 3 months and 12 months after the end of RTCT treatment, and at disease progression if applicable. Tumor tissues will be collected if available. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Biological samples | Other | blood and tumor tissue sample |
|
| Measure | Description | Time Frame |
|---|---|---|
| tumor antigen specific T-cell responses | tumor antigen specific T-cell responses | up to 12 months after the end of radiochemotherapy |
| Measure | Description | Time Frame |
|---|---|---|
| monitoring of immune checkpoints, immune cell death, immune suppressive cells and T-cell polarisation | monitoring of immune checkpoints, immune cell death, immune suppressive cells and T-cell polarisation | up to 12 months after the end of radiochemotherapy |
| Progression free survival |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Olivier ADOTEVI, Pr | Contact | +33370632212 | olivier.adotevi@univ-fcomte.fr |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CHU de Besançon | Recruiting | Besançon | 25000 | France |
Not provided
| ID | Term |
|---|---|
| D008175 | Lung Neoplasms |
| D006258 | Head and Neck Neoplasms |
| ID | Term |
|---|---|
| D012142 | Respiratory Tract Neoplasms |
| D013899 | Thoracic Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
time interval between the date of initiation of treatment and the date of first progression (local, remote [extent of the disease by RECIST v1.1] second cancer) or death from any cause |
| date of first progression of the disease (within 2 year after the initiation of the treatment)] |
| overall survival | time between the date of initiation of treatment and the date of death from any cause | date of death from any cause (within 2 years after the initiation of the treatment) |
| Quality of life related to health measured by EORTC-QLQC30 | Quality of life related to health measured by EORTC-QLQC30 | from the inclusion to patient death, up to 1 year |
| Centre Georges François LECLERC | Recruiting | Dijon | 21000 | France |
|
| Hôpital Nord Franche-Comté | Recruiting | Montbéliard | France |
|
| Institut Jean Godinot | Recruiting | Reims | France |
|
| D008171 |
| Lung Diseases |
| D012140 | Respiratory Tract Diseases |